Thermo Fisher Scientific VEGF Monoclonal Antibody (JH121)

Applications

Tested Dilution

Publications

Western Blot (WB)

1-2 µg/mL

View 18 publications 18 publications

Immunohistochemistry (IHC)

-

View 75 publications 75 publications

Immunohistochemistry (Paraffin) (IHC (P))

1:20

View 5 publications 5 publications

Immunocytochemistry (ICC/IF)

1:20-1:100

View 2 publications 2 publications

ELISA (ELISA)

-

View 3 publications 3 publications

Neutralization (Neu)

-

View 3 publications 3 publications

Miscellaneous PubMed (Misc)

-

View 2 publications 2 publications

Product Specifications

Species Reactivity

Human, Mouse, Rabbit

Published species

Avian, Bovine, Dog, Horse, Human, Mouse, Rabbit, Rat

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

JH121

Immunogen

Recombinant human VEGF121

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.2 mg/mL

Purification

Protein G

Storage buffer

PBS, pH 7.4, with 0.2% BSA

Contains

0.09% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_10981661

Product Specific Information

MA5-13182 targets Vascular Endothelial Growth Factor in IF, WB, ICC, IHC, IP and ELISA applications and shows reactivity with Human and Rabbit samples.

Target Information

VEGF (vascular endothelial growth factor) which is a 45 kDa homodimeric, disulfide-linked glycoprotein involved in angiogenesis which promotes tumor progression and metastasis. VEGF has a variety of effects on vascular endothelium, including the ability to promote endothelial cell viability, mitogenesis, chemotaxis, and vascular permeability. The VEGF family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis. Most tumors have the absolute requirement of angiogenesis, and VEGF has been described as the most potent angiogenic cytokine linked to this process. To date 5 different isoforms of VEGF have been described. These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells. VEGF and its high-affinity binding receptors, the tyrosine kinases FLK1 and FLT1, are thought to be important for the development of embryonic vasculature. Studies have shown that an alternately spliced form of FLT1 produces a soluble protein, termed sFLT1, which binds vascular endothelial growth factor with high affinity, playing an inhibitory role in angiogenesis. Elevated levels of VEGF is linked to POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, Skin changes) also known as Crow-Fukase syndrome which affects multiple organs in the body.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.